All Stories

  1. Corticosteroids in severe community-acquired pneumonia: friend, foe or both?
  2. Transforming post-acute pneumonia management: risk stratification using machine learning
  3. Nuevas perspectivas en la neumonía adquirida en la comunidad en el adulto
  4. Corticosteroids and hospital-acquired pneumonia
  5. The pneumonia challenge: time to end the global neglect
  6. Immunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes
  7. Critical Challenges: Respiratory Infections in Immunocompromised ICU Patients
  8. Pulse oximetry to optimise first-line care and save children’s lives: evidence from the AIRE project in West Africa
  9. Why RSV Infection Matter in Older Adults? The Urgent Need for Vaccination
  10. Pulmonary Infections in Patients with Human Immunodeficiency Virus Infection
  11. Identifying predictors of treatment failure with community-acquired pneumonia: an update
  12. Risk Factors and Outcomes Associated With Polymicrobial Infection in Community-Acquired Pneumonia
  13. Infecciones por el virus respiratorio sincitial en los adultos
  14. Viral community-acquired pneumonia: what’s new since COVID-19 emerged?
  15. Coronavirus Disease 2019 and Emerging Lung Infections in the Immunocompromised Patient
  16. Adult vaccinations against respiratory infections
  17. Healthcare worker views on antimicrobial resistance in chronic respiratory disease
  18. Mechanical power is not associated with mortality in COVID-19 mechanically ventilated patients
  19. World Pneumonia Day 2024: Fighting Pneumonia and Antimicrobial Resistance
  20. Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia
  21. Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia
  22. Outcomes of corticosteroid therapy in patients with viral community-acquired pneumonia
  23. Epidemiology, ventilation management and outcomes of COVID–19 ARDS patients versus patients with ARDS due to pneumonia in the Pre–COVID era
  24. A review of the value of point-of-care testing for community-acquired pneumonia
  25. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia
  26. Diabetes Mellitus and Pneumococcal Pneumonia
  27. The association of premorbid conditions with 6-month mortality in acutely admitted ICU patients over 80 years
  28. Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort
  29. Viral Pneumonia: From Influenza to COVID-19
  30. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
  31. World Pneumonia Day 2023: the rising global threat of pneumonia and what we must do about it
  32. Clinical Outcomes of Critical COVID-19 in HIV-Infected Adults: A Propensity Score Matched Analysis
  33. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review
  34. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantStaphylococcus aureuspneumonia
  35. Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?
  36. Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia
  37. Interventions to improve outcomes in community-acquired pneumonia
  38. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)
  39. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients
  40. A Novel Approach to Temperature Profiling in Relation to Clinical Outcomes in Oncological Patients with Neutropenia
  41. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients
  42. Características clínicas y epidemiológicas de las muertes por dengue durante un brote en el norte del Perú
  43. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report
  44. Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study
  45. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
  46. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain
  47. Advances in molecular diagnostic tests for community-acquired pneumonia
  48. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia
  49. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia
  50. Hyperglycemia in Acute Critically Ill COVID-19 Patients
  51. Validation of IDSA/ATS Guidelines for ICU Admission in Adults Over 80 Years Old With Community-Acquired Pneumonia
  52. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia
  53. Host-targeted approaches to sepsis due to community-acquired pneumonia
  54. Differences between sexes concerning COVID-19-related pneumonia
  55. Respiratory viruses: their importance and lessons learned from COVID-19
  56. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia
  57. Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study
  58. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study
  59. Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome
  60. Aspiration pneumonia
  61. Ceftaroline in severe community-acquired pneumonia
  62. Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications
  63. Biomarcadores biológicos en las enfermedades respiratorias
  64. [Translated article] Biological Biomarkers in Respiratory Diseases
  65. What's Next in Pneumonia?
  66. Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis
  67. Severe Infections Due to Respiratory Viruses
  68. One-year mortality after ICU admission due to COVID-19 infection
  69. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study
  70. Management of pneumonia in critically ill patients
  71. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study
  72. COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital
  73. Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis
  74. Management and outcomes in critically ill nonagenarian versus octogenarian patients
  75. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients
  76. Outcomes of Critically ill Very old patients with Acute Respiratory Distress Syndrome and Community-Acquired Pneumonia
  77. Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis
  78. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  79. Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study
  80. Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial
  81. Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study
  82. Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study
  83. Pulse oximetry is an essential tool that saves lives: a call for standardisation
  84. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
  85. Provision of critical care for the elderly in Europe: a retrospective comparison of national healthcare frameworks in intensive care units
  86. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort
  87. Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia
  88. The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011–2018
  89. Pneumonia
  90. Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis
  91. Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain
  92. Frailty is associated with long-term outcome in patients with sepsis who are over 80 years old: results from an observational study in 241 European ICUs
  93. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia
  94. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study
  95. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia
  96. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study
  97. Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes
  98. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  99. Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience
  100. PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community
  101. Awareness and Pneumonia knowledge: where to start educating?
  102. Methicillin-susceptible Staphylococcus aureus in Community-Acquired Pneumonia: Risk Factors and Outcomes
  103. Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease
  104. SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities
  105. The importance of airway and lung microbiome in the critically ill
  106. Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019
  107. Q Fever (Coxiella Burnetii)
  108. Promoting the use of social networks in pneumonia
  109. Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens
  110. Advances in molecular diagnostic tests for pneumonia
  111. Are Macrolides as Effective as Fluoroquinolones in Legionella Pneumonia? Yes, but…
  112. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
  113. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain
  114. Gender differences in community-acquired pneumonia
  115. Community-acquired pneumonia in critically ill very old patients: a growing problem
  116. Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators
  117. Can Artificial Intelligence Improve the Management of Pneumonia
  118. Programmed ‘disarming’ of the neutrophil proteome reduces the magnitude of inflammation
  119. A multicentre analysis of Nocardia pneumonia in Spain: 2010–2016
  120. Non-invasive ventilation in palliative care: a systematic review
  121. Reply to Musher
  122. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning
  123. An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria
  124. The contribution of frailty, cognition, activity of daily life and comorbidities on outcome in acutely admitted patients over 80 years in European ICUs: the VIP2 study
  125. New antibiotics for community acquired pneumonia
  126. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients
  127. Prevalence and risk factors of sepsis in very old patients with CAP
  128. Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia
  129. Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?
  130. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia
  131. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis
  132. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  133. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia
  134. non invasive diagnosis of nosocomial pneumonia
  135. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  136. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired pneumonia
  137. lymphopenia predicts mortality in patients with ICU pneumonia
  138. Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
  139. Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults
  140. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
  141. PES Pathogens in Severe Community-Acquired Pneumonia
  142. An international perspective on hospitalized patients with viral community-acquired pneumonia
  143. Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia
  144. Community-acquired pneumonia as an emergency condition
  145. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients with Community-Acquired Pneumonia
  146. Reply to Head and Keynan
  147. Drugs that increase the risk of community-acquired pneumonia: a narrative review
  148. Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART
  149. Clinical Approach to Community-acquired Pneumonia
  150. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study
  151. Inflammatory response depends on time since onset of symptoms in pneumonia
  152. MagicplexTM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
  153. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
  154. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  155. Community-acquired bacterial pneumonia in adult HIV-infected patients
  156. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease
  157. Community-acquired Pneumonia and Acute Respiratory Distress Syndrome
  158. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
  159. Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study
  160. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
  161. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis
  162. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia
  163. Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients
  164. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
  165. New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study
  166. Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress
  167. Has Mortality of Community-Acquired Pneumonia Really Reduced?
  168. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia
  169. Adjuvant therapies in critical care: steroids in community-acquired pneumonia
  170. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia
  171. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality
  172. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
  173. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
  174. Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia
  175. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients
  176. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial
  177. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia
  178. Risk factors for community-acquired pneumonia in adults
  179. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia
  180. Typical Presentation of Legionella pneumophila Community-Acquired Pneumonia
  181. Research in community-acquired pneumonia: the next steps
  182. Seasonality of pathogens causing community-acquired pneumonia
  183. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns
  184. Laboratory diagnosis of pneumonia in the molecular age
  185. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
  186. Clinical management of community acquired pneumonia in the elderly patient
  187. Community-Acquired Pneumonia 2000-2015: What is New?
  188. Response
  189. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa
  190. Community-acquired pneumonia related to intracellular pathogens
  191. Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
  192. What is the clinical relevance of drug-resistant pneumococcus?
  193. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia
  194. Pneumococcal vaccination
  195. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  196. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis
  197. Severe community-acquired pneumonia: Corticosteroids as adjunctive treatment to antibiotics
  198. Bronchiectasis in rare pulmonary diseases: A case series
  199. Bacteraemia in outpatients with community-acquired pneumonia
  200. Polymicrobial community-acquired pneumonia: An emerging entity
  201. Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia
  202. Bacteraemia in outpatient with community-acquired pneumonia
  203. Ceftobiprole for the treatment of pneumonia: a European perspective
  204. Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series
  205. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients
  206. New antimicrobial approaches to gram positive respiratory infections
  207. Macrolide resistance and outcomes of patients with Streptococcus pneumoniae pneumonia.
  208. Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia
  209. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis
  210. Severe community-acquired pneumonia: Severity and management
  211. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update
  212. Clinical Management of Bacterial Pneumonia
  213. Viral infections
  214. Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia
  215. Severity and outcomes of community acquired pneumonia in asthmatic patients
  216. Predicting treatment failure in patients with community acquired pneumonia: a case-control study
  217. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  218. Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature
  219. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study
  220. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome
  221. IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia
  222. Pneumococcal disease: Epidemiology and new vaccines
  223. Community-acquired viral pneumonia in human immunodeficiency virus infected patients
  224. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis
  225. Predicting Community-Acquired Pneumonia Etiology: Response
  226. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia
  227. IgM levels in plasma predict outcome in severe pandemic influenza
  228. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study
  229. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
  230. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1
  231. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia
  232. Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia
  233. Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza A (H1N1)
  234. Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome
  235. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
  236. Influenza A (H1N1) Pneumonia
  237. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
  238. Invasive Pneumococcal Disease Today
  239. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia
  240. Entendimento da mortalidade em pneumonia pneumocócica bacterêmica
  241. Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia
  242. Pulmonary Complications Of Pneumococcal CAP: Incidence, Predictors, And Outcomes
  243. Corticosteroids In Community-Acquired Pneumonia: Therapeutic Reasons And Outcomes
  244. Influence Of Long-Term Use Of Inhaled Corticoids On The Development Of Pleural Effusion In Community Acquired Pneumonia
  245. Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia
  246. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza
  247. Community-acquired pneumonia in outpatients: aetiology and outcomes
  248. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients
  249. CAP IN COPD PATIENTS
  250. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1
  251. First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain
  252. Microbial aetiology of community-acquired pneumonia and its relation to severity
  253. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
  254. Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients
  255. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic
  256. Correction
  257. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia
  258. Severe Mixed Community Acquired Pneumoniae
  259. Community-acquired Pneumonia In Outpatients: Microbial Etiology
  260. INDICATION OF PLEURAL DRAINAGE IN PARAPNEUMONIC EFFUSION: ADHERENCE TO THE AMERICAN COLLEGE OF CHEST PHYSICIANS’ GUIDELINES
  261. PARAPNEUMONIC EFFUSIONS ACCORDING TO THE CLASSIFICATION OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS: CLINICAL CHARACTERISTICS
  262. Healthcare-associated Pneumonia (HCAP): Clinical Features And Biomarkers
  263. Nursing home-acquired pneumonia: a 10 year single-centre experience
  264. Impact of Smoking Habit on the Etiology of Community-Acquired Pneumonia (CAP).
  265. Community-Acquired Pneumonia: Etiology and Severity Scores.
  266. Complicated Pneumococcal Pneumonia in Adults.
  267. Severe community-acquired pneumonia